CD8A and neoplasm: We performed a dynamic in vitro killing assay with a 1:1 ratio of cognate, antigen-specific (PMEL), activated CD8+ T cells and B16-F10 tumor cells or IFNγ-pretreated B16-F10 tumor cells.